





Cellmid Limited (ASX:CDY)
Annual Report
ABN 69 111 304 119

Suite 204, Level 2
55 Clarence Street
Sydney NSW 2000

T: +61 2 9221 6830
F: +61 2 9221 8535
E: info@cellmid.com.au
W: www.cellmid.com.au

CONTENTS

04

Chairman’s Letter

06

CEO Report

10

Directors’ Report

25

Corporate Governance

27

Annual Financial Report

68

Additional Information for Listed Entities

70

Corporate Directory

DIRECTORS' REPORT

The Directors present their report, together with the financial statements of the Group, being Cellmid Limited ("the Company") and the entities it controlled, for the financial year ended 30 June 2019.

1. GENERAL INFORMATION

Information on Directors

The names, qualifications, experience and special responsibilities of each person who has been a Director during the year and to the date of this report are:

Dr David King	Chairman (Non-executive)
Qualifications	PhD in Seismology, Australian National University, Fellow of The Australian Institute of Company Directors, Fellow of the Australian Institute of Geoscientists
Experience	Experience as chairman, executive and non-executive director in high growth companies, across a variety of sectors, with focus on governance issues in publicly listed companies.
Interest in shares and options	Shares: 200,000 directly held Shares: 1,200,000 indirectly held
Special responsibilities	Member of the Audit and Risk Committee and member of the Nomination and Remuneration Committee
Other directorships in listed entities held in the previous three years	Current directorships - Litigation Capital Management Ltd, Galilee Energy Limited, African Petroleum Corporation, Tap Oil Ltd and Renergen Ltd.
Ms Maria Halasz	Managing Director (Chief Executive Officer)
Qualifications	MBA, BSc in Microbiology, University of Western Australia, Graduate of the Australian Institute of Company Directors
Experience	26 years' experience in life sciences working in executive positions in private and public companies, then managing investment funds and later holding senior positions in corporate finance specialising in life sciences. Maria has been CEO and Managing Director of Cellmid since April 2017.
Interest in shares and options	Shares: 420,000 directly held Shares: 1,599,938 indirectly held
Special responsibilities	Managing Director and Chief Executive Officer
Other directorships in listed entities held in the previous three years	None

Mr Bruce Gordon	Director (Non-executive)
Qualifications	BA, Macquarie University, Fellow of The Institute of Chartered Accountants Australia and New Zealand, Fellow of The Australian Institute of Company Directors
Experience	An audit and corporate finance specialist, and an experienced finance professional with a career spanning more than 35 years advising and providing financial services to private and publicly listed companies as well as subsidiaries of large multinationals.
Interest in shares and options	Shares: 110,000 indirectly held
Special responsibilities	Chairman of the Audit and Risk Committee and member of the Nomination and Remuneration Committee
Other directorships in listed entities held in the previous three years	None

Dr Fintan Walton	Director (Non-executive)
Qualifications	PhD, Genetics, Trinity College Dublin
Experience	Founder and CEO of PharmaVentures Ltd, a UK based corporate advisory firm that provides advice on all aspects of corporate transactions, business brokering, mergers and acquisitions and licensing deals to a diversified global network.
Interest in shares and options	Shares: 12,500 directly held Shares: 52,500 indirectly held
Special responsibilities	Member of the Nomination and Remuneration Committee
Other directorships in listed entities held in the previous three years	None

Dr Martin Cross	Director (Non-executive)
Qualifications	PhD. Microbiology, Aberdeen University Scotland. Fellow of the Australia Institute of Company Directors.
Experience	Over 30 years' experience working in the pharmaceutical and biotech industries primarily in all aspects of marketing, selling and business management. This included global roles at international Headquarters of AstraZeneca and Novartis. Former Country President for Novartis Australia/NZ, Managing Director for Alphapharm (Mylan) Australia/NZ and Chairman of the Generics Industry Association and Medicines Australia.
Interest in shares and options	Shares: 175,000 indirectly held
Special responsibilities	Member of the Audit and Risk Committee
Other directorships in listed entities held in the previous three years	Non-Executive Director Oncosil Ltd
Other	Non-Executive Director NHMRC National Institute of Dementia Research, Advisor Pursuit Sports Pty Ltd, Advisor University of Technology Sydney (Pharmacy Commercial Advisory Board)



Cellmid Limited
Suite 204, Level 2
55 Clarence Street
Sydney NSW 2000
ABN 69 111 304 119

T +61 2 9221 6830
F +61 2 9221 8535
E info@cellmid.com.au
W www.cellmid.com.au